Comparison of the Chondrogenic Differentiation Potential of Equine Synovial Membrane-Derived and Bone Marrow-Derived Mesenchymal Stem Cells.
Authors: Gale Alexis L, Linardi Renata L, McClung George, Mammone Renata M, Ortved Kyla F
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Focal cartilage injuries frequently trigger osteoarthritis progression in horses, making effective regenerative therapies a priority for practitioners. This 2019 study directly compared mesenchymal stem cells (MSCs) isolated from synovial membrane and bone marrow in six adult horses, hypothesising that synovial-derived cells might offer superior chondrogenic potential due to shared embryological origin with cartilage; the researchers assessed immunophenotype, proliferation rates, and differentiation capacity using flow cytometry, gene expression analysis (ACAN, COL2b, SOX9), and histological evaluation over 28 days of culture. Contrary to expectations, both cell sources demonstrated equivalent chondrogenic differentiation with similar proteoglycan deposition and gene expression profiles, whilst bone marrow-derived MSCs showed significantly greater osteogenic capacity. For practitioners considering MSC therapy, these findings indicate that synovial membrane represents a viable and potentially less invasive harvest site, though clinicians should not anticipate superior cartilage-forming properties under standard in vitro culture conditions; the practical advantage may instead lie in collection accessibility rather than biological superiority of chondrogenesis.
Read the full abstract on PubMed
Practical Takeaways
- •Synovial membrane-derived stem cells do not show the expected chondrogenic advantage over bone marrow sources for cartilage repair in horses using standard culture methods
- •Both cell sources are viable for potential therapeutic use, but current differentiation protocols do not favour one source over the other for cartilage regeneration
- •Further research into enhanced culture conditions or priming methods may be needed to unlock the theoretical advantage of synovial-derived cells
Key Findings
- •SM-MSCs and BM-MSCs showed similar immunophenotypes, with both expressing stem cell markers (CD29, CD44, CD90, CD105, MHCI)
- •Chondrogenic differentiation was not significantly different between SM-MSCs and BM-MSCs in proteoglycan content and gene expression (ACAN, COL2b, SOX9)
- •BM-MSCs demonstrated enhanced osteogenic differentiation compared to SM-MSCs
- •Synovial membrane is a feasible but not superior source of MSCs for cartilage repair in horses under current in vitro culture conditions